A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (MSP3LSP)
Randomized, Controlled, Dose Escalation Phase Ib Trial of MSP 3 LSP Adjuvanted in Aluminium Hydroxide Versus Hepatitis Bin 12 to 24 Month Old Children in Burkina Faso.
Study Overview
Status
Conditions
Detailed Description
The study is a single centre randomized controlled and blinded study (observer blind). It will be conducted at the CNRFP Vaccinology unit located in Balonghin. Children in the catchments area within the 1-2 years age group, whose parents consent will be screened to randomise 45 eligible participants. Two MSP 3 dose levels will be evaluated; 15µg and 30µg. The study will start with immunizing older children with the lowest dose observing safety parameters closely, then proceed to to the higher dose with a two week of observation apart.
Clinical, biological and immune response data gathered after vaccination with 15µg and 30µg MSP 3 LSP will be compared to:
- The children's baseline data before vaccinations, and
- The post vaccination data of children in the control group.
Randomization will ensure that the comparison groups are similar in relevant characteristics at baseline. The concealment of allocation before enrolment will further enforce the randomisation. Individuals who will make the assessment of the study end points will be completely blinded of the vaccine administered. This will ensure that there is no observer bias. Further, reporting or information bias will be minimised, because the recipients will also not be aware of which vaccine they have been administered. This is possible because the selected control vaccine has not been in routine use in this area, and has only now been recommended by the Ministry of Health. Cross over immunisation at the end of the trial will involve only those children who will received the study vaccine; they will be administered the control vaccine in the interest of public health benefits for them.
The schedule of vaccination at 0, 1 and 2 months has been adopted because it is suitable for the target group. The idea is to eventually deploy the vaccine through the expanded programme on immunisation should the vaccine become registered for public use. For the EPI age group, it is not only an efficient delivery mechanism, but they are also the most vulnerable group to malaria.
In brief, the groups will be allocated as follows:
- Group 1: 23 participants (15 receiving MSP-3 vaccine 15 µg and 8 receiving Hepatitis B vaccine).
- Group 2: 22 participants (15 receiving MSP-3 vaccine 30 µg and 7 receiving Hepatitis B vaccine)
Immunization schedule will be 0, 1, and 2 months for all cohorts and provisionally as following for each group:
Study days 0, 28 and 56 for group 1; and Study days 14, 42, 70 for group 2 Vaccinations of groups 1 and 2 will be staggered: immunization in group 2 will start 2 weeks after group 1. This interval may be extended if deemed necessary due to SAEs or other safety concerns.Randomization will be done for each group at the times of first vaccinations.Route of inoculation will be by subcutaneous injection into right or left deltoid (alternately).
Each child will be observed for at least 60 minutes after vaccination to evaluate and treat any acute adverse events (AEs). Study duration will be approximately 13 months per participant. There will be a seven (7) day follow-up period for solicited adverse events (day of vaccination plus 6 subsequent days); and twenty eight (28) day follow-up period for unsolicited adverse events (Vaccination day plus 27 subsequent days). The follow-up for serious adverse events (SAE's) will be for 12 months following the first dose of study vaccine (9 months after dose 3).
At the end of the follow-up period for unsolicited AEs (i.e., one month after the third dose), participants will be followed by field workers at home at monthly intervals to record SAEs. For data collection, conventional paper Case Report Forms (in triplicate copies) will be used.
An interim analysis is foreseen after day 84 of follow up. At this stage decision will be considered whether to proceed to a phase 2b study or not, and with which dosage of MSP 3, based on the safety and immunogenicity profile.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Sapone
-
Ouagadougou, Sapone, Burkina Faso
- Recruiting
- Projet de Développement de Vaccins Anti-Paludique- Centre National de Recherche et de Formation sur le Paludisme
-
Contact:
- Amidou T Konate, MD
- Phone Number: 6 226-5032-4695
- Email: amidou@fasonet.bf
-
Contact:
- Alphonse Ouedraogo, MD
- Phone Number: 8 226-5032-4695
- Email: Alphonse.ouedraogo@voila.fr
-
Principal Investigator:
- Sodiomon B Sirima, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 1-2 years old
- Healthy by medical history and physical examination
- Signed Informed Consent by guardian/parent
- Resident in the study area village during the whole trial period
Exclusion Criteria:
- Symptoms, physical signs of disease that could interfere with the interpretation of the trial results or compromising the health of the subjects
- Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior recruitment. (for corticosteroids, this will mean prednisone, or equivalent,0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- Cannot be followed for any social, psychological or geographical reasons.
- Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to 30 days after the third dose.
- Suspected or known hypersensitivity to any of the vaccine components or to previous vaccine.
- Laboratory abnormalities on screened blood samples out of range, more specifically refer to table 2.
- Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an EPI or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria, pertussis,tetanus vaccines) which may be given 14 days or more before or after vaccination
- Evidence of chronic or active hepatitis B infection
- Presence of chronic illness that, in the judgement of the investigator, would interfere with the study outcomes or pose a threat to the participant's health.
- Administration of immunoglobulin andor any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
- History of surgical splenectomy.
- Moderate or severe malnutrition at screening defined as weight for age Z score less than 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
15 microgramme candidate vaccine group
|
Lyophilized vaccine given at 15 or 30 microgrammes
|
|
Active Comparator: 2
Hepatitis B comprator group
|
Hepatitis vaccine adjuvanted in Aluminium hydroxide
|
|
Experimental: 3
30 microgrammes candidate vaccine group
|
Lyophilized vaccine given at 15 or 30 microgrammes
|
|
Active Comparator: 4
Hepatitis B vaccine group
|
Hepatitis B vaccine adjuvanted in Aluminium hydroxide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Immediate reactogenicity (within 1 hour, with emphasis on allergic reactions)
Time Frame: 7 days
|
7 days
|
|
Local and systemic reactogenicity during the 7 days following the vaccine
Time Frame: 7 days
|
7 days
|
|
Unsolicited adverse events occurring within 28 days following each vaccination
Time Frame: 28 Days
|
28 Days
|
|
Serious adverse events (SAE) throughout the study period
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Humoral immune responses by ELISA before and four weeks after each vaccination
Time Frame: 84 Days
|
84 Days
|
|
Cellular immune response to the vaccine antigens by measuring the
Time Frame: 84 Days
|
84 Days
|
|
number of cells producing IFNγ/106 cells by Elispot to MSP3-LSP and
Time Frame: 84 Days
|
84 Days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Issa Nebie, PhD, Projet de Développement de Vaccins Anti-Paludique- Centre National de Recherche et de Formation sur le Paludisme
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSP3_BF_0302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.